Table 1 |
||
|
Baseline characteristics of the ESPOIR patients who received methotrexate or its equivalent as a first-line biologic agent for rheumatoid arthritis. |
||
|
SD-treated patients (number = 370) |
All ESPOIR patients (number = 813) |
|
|
|
||
|
Age, years |
49.4 ± 11.4 (51.5) |
48.1 ± 12.5 (50.1) |
|
Female sex |
271 (73.2%) |
624 (76.7%) |
|
Disease duration, weeks |
15.2 ± 15.4 (57.7) |
31.6 ± 37.1 (21.3) |
|
Swollen joint count in 28 joints |
7.9 ± 5.4 (7) |
7.2 ± 5.4 (6) |
|
Tender joint count in 28 joints |
8.7 ± 6.9 (7) |
8.4 ± 7 (6) |
|
ESR, mm/1st hour |
32.7 ± 25 (26) |
29.4 ± 24.6 (22) |
|
CRP, mg/L |
24.8 ± 37.7 (11) |
20.3 ± 32.4 (9) |
|
DAS28(ESR)-4v |
5.4 ± 1.2 (5.2) |
5.1 ± 1.3 (5.1) |
|
IgM RF positivity |
204 (55.1%) |
376 (45.8%) |
|
ACPA positivity |
185 (50%) |
315 (38.8%) |
|
Typical erosion on radiographs |
66 (17.8%) |
100 (13.6%) |
|
vSHS score |
6.02 ± 9.7 [54] |
3.71 ± 5.71 [54] |
|
ACR/EULAR 2010 criteria |
316 (85.4%) |
582 (79.1%) |
|
HAQ score |
1.03 ± 0.7 (1) |
0.979 ± 0.684 |
|
First-line agent: |
||
|
- No DMARDs |
n.a. |
207 (25.5%) |
|
- DMARDs without structural effect |
n.a. |
117 (14.4%) |
|
- Methotrexate or leflunomide |
370 (100%) |
396 (48.7%) |
|
- Other DMARDs with structural effect |
n.a. |
56 (6.9%) |
|
- Tumor necrosis factor blockers alone or in combination |
n.a. |
37 (4.6%) |
|
|
||
|
Data are mean ± SD (median) or number (%); n.a.; not available. Baseline CRP level (normally < 10 mg/l), IgM and IgA RF (ELISA, Menarini, France; positive > 9 UI/ml) and anti-CCP2 antibodies (ACPA; ELISA, DiaSorin, France; positive > 50 U/ml) were detected in all patients with the same technique in a central lab (Paris-Bichat). ACPA, anti-citrullinated protein antibody; ACR/EULAR, American College of Rheumatology/European League Against Rheumatism; CRP, C-reactive protein; DAS28(ESR)-4v, Disease Activity Score in 28 joints-4 variables, using erythrocyte sedimentation rate; DMARD, disease-modifying anti-rheumatic drugs; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; IgM, immunoglobulin M; RF, rheumatoid factor; SD, synthetic DMARD; vSHS, van der Heijde-modified Sharp score. |
||
|
Fautrel et al. Arthritis Research & Therapy 2012 14:R249 doi:10.1186/ar4092 |
||
